Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.

about

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.

Item

http://www.wikidata.org/entity/Q55491553

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Radiation therapy and PD-1/PD- ...... olving anticancer combination.

@en

Radiation therapy and PD-1/PD- ...... olving anticancer combination.

@nl

type

Item

label

Radiation therapy and PD-1/PD- ...... olving anticancer combination.

@en

Radiation therapy and PD-1/PD- ...... olving anticancer combination.

@nl

prefLabel

Radiation therapy and PD-1/PD- ...... olving anticancer combination.

@en

Radiation therapy and PD-1/PD- ...... olving anticancer combination.

@nl

P1476

Radiation therapy and PD-1/PD- ...... olving anticancer combination.

@en

P2093

Andrew E Hendifar

http://www.w3.org/2001/XMLSchema#string

Jun Gong

http://www.w3.org/2001/XMLSchema#string

Richard Tuli

http://www.w3.org/2001/XMLSchema#string

Thang Q Le

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

Combining radiotherapy and cancer immunotherapy: a paradigm shift

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

P2888

s40425-018-0361-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S40425-018-0361-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Erminia Massarelli

P577

2018-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104385549

http://www.w3.org/2001/XMLSchema#string

P698

29866197

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

membrane proteins

P932

5987486

http://www.w3.org/2001/XMLSchema#string